A supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) received FDA approval for efficacy on 2026-05-08. This approval, documented under BLA 761304 S-18, signifies an expansion of the drug's approved uses or populations based on new efficacy data.
Background
This event pertains to a supplemental application for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)), which received FDA approval for efficacy. Supplemental approvals typically expand the approved uses, dosing, or patient populations for an already approved drug, based on new clinical evidence demonstrating additional efficacy.
What this means
The FDA's supplemental approval for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) for efficacy on 2026-05-08 indicates that new clinical data supported an expansion of the drug's approved therapeutic scope. While specific details of the new indication or patient population are not provided in the available data, such approvals typically allow for broader use of the medication, potentially impacting patient care by offering an additional treatment option or improving outcomes for a specific group of patients.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 761304 S-18, concerning Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)), was documented on 2026-05-08 on accessdata.fda.gov.